Last updated: 2026-09-08 22:19:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Mannkind Corporation (MNKD) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $4.17, with a market capitalization of $1.31B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.23 to $6.51. This page covers its latest market performance, valuation, price trends and company information.
$1.31B | |
$4.00 | |
$121.55 | |
$0.67 | |
$4.06 | |
4.18M | |
4.51M | |
-- | |
$6.51 | |
$2.23 | |
-- | |
-- |
Mannkind Corporation (MNKD) is trading at $4.15 in after-hours trading as of 2026-09-08 21:40:00, up 2.22% ($0.09) from the regular-session close of $4.06.
After-hours trading shows how investors are pricing MNKD after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Mannkind Corporation (MNKD) moved from $4.06 to $4.17, representing a gain of 2.59% ($0.11).
The stock traded between $3.90 and $4.32 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 2.40 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 45.2%
MNKD is currently trading at $4.17, placing it 45.2% of the way from its 52-week low of $2.23 to its 52-week high of $6.51. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 592 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Mannkind Corporation (MNKD) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.